Shockley TR, Lin K, Nagy JA, Tompkins RG, Dvorak HF, Yarmush ML: Penetration of tumor tissue by antibodies and other immunoproteins. Ann NY Acad Sci 617:367–382, 1991.
Byers VS, Baldwin RW: Therapeutic strategies with monoclonal antibodies and immunoconjugates. Immunol 65:329–335, 1988.
Vaickus L, Foon KA: Overview of monoclonal antibodies in the diagnosis and therapy of cancer. Cancer Invest 9:195–209, 1991.
Lowder JN, Meeker TC, Campbell M, Garcia CF, Gralow J, Miller RA, Warnke R, Levy R: Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: Correlation with clinical responses. Blood 69:199–210, 1987.
Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr JW, Thorpe PE: A Phase I immunotoxin trial in patients with B cell lymphoma. Cancer Res 15:4052–4058, 1991.
Burrows FJ, Watanabe Y, Thorpe PE: A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. Cancer Res 52:5954–5962, 1992.
Dvorak HF, Nagy JA, Dvorak AM: Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 3:77–85, 1991.
Baxter LT, Jain RK: Transport of fluid and macromolecules in tumors. Micro Res 41:5–23, 1991.
Sands H: Radioimmunoconjugates: an overview of problems and promises. Antibody Immunoconjugates and Radiopharm 1:213–226, 1988.
Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J: Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 46:3183–3191, 1986.
Jain RK: Transport of molecules in the tumor interstitium. Cancer Res 47:3039–3051, 1987.
Jain RK, Baxter LT: Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 48:7022–7032, 1988.
Jain RK: Transport of molecules across tumor vasculature. Cancer Metastasis Rev 6:559–594, 1987.
Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, Weinstein JN: Micropharmacology of monoclonal antibodies in solid tumors; direct experimental evidence for a binding site barrier. Cancer Res 52:5144–5153, 1992.
Denekamp J: Vasculature as a target for tumour therapy. Prog Appl Microcirc 4:28–38, 1984.
Denekamp J: Endothelial cell attack as a novel approach to cancer therapy. Cancer Top 6:6–8, 1986.
Jaffe EA: Biology of Endothelial Cells. Martinus Nijhoff, Boston, 1984.
Burrows FJ, Thorpe PE: Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 90:8996–9000, 1993.
Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, Thorpe PE: Endoglin is an endothelial cell proliferation marker that is upregulated in tumor vasculature. Clin Cancer Res, submitted.
Gougos A, Letarte M: Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265:8361–8364, 1990.
Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M: Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267:19027–19030, 1992.
Gougos A, Letarte M: Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 141:1925–1933, 1988.
Gougos A, St.Jacques S, Greaves A, O'Connell PJ, d'Apice AJF, Buhring HJ, Bernabeu C, Vanmourik JA, Letarte M: Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells and syncytiotrophoblasts. Int Immunol 4:83–92, 1992.
O'Connell PJ, McKenzie A, Fisicaro N, Rockman SP, Pearse MJ, d'Apice AJF: Endoglin: a 180-kD endothelial cell and macrophage restricted differentiation molecule. Clin Exp Immunol 90:154–159, 1992.
Buhring HJ, Muller CA, Letarte M, Gongos A, Saalmuller A, van Agthoven AJ, Busch FW: Endoglin is expressed on a subpopulation of immature erythroid cells or normal bone marrow. Leukemia 5:841–847, 1991.
Westphal JR, Willems HW, Schalkwijk CJ, Ruiter DJ, deWaal RM: A new 180-kDa dermal endothelial cell activation antigen:in vitro andin situ characteristics. J Invest Dermatol 100:27–34, 1993.
Darzynkiewicz Z, Traganos F, Sharpless T, Melamed MR: Lymphocyte stimulation: a rapid multiparameter analysis. Proc Natl Acad Sci USA 73:2881–2884, 1976.
Hobson B, Denekamp J: Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 49:405–413, 1984.
Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown ANF, Watson GJ, Blakey DC, Newell DR: Improved anti-tumor effects of immunotoxins prepared with deglycosylated ricin A chain and hindered disulfide linkages. Cancer Res 48:6396–6403, 1988.
Engert A, Brown A, Thorpe P: Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins. Leuk Res 15:1079–1086, 1991.
Press OW, Martin PJ, Thorpe PE, Vitetta ES: Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. J Immunol 141:4410–4417, 1988.
Hagemeier HH, Vollmer E, Goerdt S, Schulze-Osthoff K, Sorg C: A monoclonal antibody reacting with endothelial cells of budding vessels in tumours and inflammatory tissues and non-reactive with normal adult tissues. Int J Cancer 38:481–488, 1986.
Rettig WJ, Garinchesa P, Healey JH, Su SL, Jaffe EA, Old LJ: Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 89:10832–10836, 1992.
Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD: A monoclonal antibody detected heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 54:363–370, 1993.
Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natali PG: A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 108:1139–1148, 1989.
Bruland OS, Fodstad O, Stenwig AE, Pihl A: Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen. Cancer Res 48:5302–5309, 1988.
Senger DR, Vandewater L, Brown LF, Nagy JA, Yeo K-T, Yeo T-K, Berse B, Jackman RW, Dvorak AM, Dvorak HF: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer & Metastasis Reviews 12:303–324, 1993.
Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Vandewater L, Senger DR: Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors — concentration in tumor blood vessels. J Exp Med 174:1275–1278, 1991.
Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845, 1992.
Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848, 1992.
Schlingemann RO, Rietveld FJ, de Waal RM, Bradley NJ, Skene AI, Davies AJ, Greaves MF, Denekamp J, Ruiter DJ: Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 62:690–696, 1990.
Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, Sutherland DR, Baker MA, Greaves MF: Expression of the CD34 gene in vascular endothelial cells. Blood 75:2417–2426, 1990.
Schlingemann RO, Dingjan GM, Emeis JJ, Block J, Warnaar SO, Ruiter DJ: Monoclonal antibody PAL-E specific for endothelium. Lab Invest 52:71–76, 1985.
Plate KH, Breier G, Farrell CL, Risau W: Plateletderived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest 67:529–534, 1992.
Franklin WA, Christison WH, Colley M, Montag AG, Stephens JK, Hart CE:In situ distribution of the alpha-subunit of platelet-derived growth factor receptor in nonneoplastic tissue and in soft tissue tumors. Cancer Res 50:6344–6348, 1990.
Jakeman LB, Winer J, Bennett GL, Altar A, Ferrara N: Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 89:244–253, 1992.
Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis — a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875–1887, 1992.
Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120–1124, 1992.
Chodak GW, Haudenschild C, Gittes RF, Folkman J: Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder. Ann Surg 192:762–771, 1980.
Sillman F, Boyce J, Fruchter R: The significance of atypical vessels and neovascularization in cervical neoplasia. Am J Obstet Gynecol 139:154–159, 1981.
Burrows FJ, Thorpe PE: Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 90:8996–9000, 1994.
Burrows FJ, Thorpe PE: Targeting the vasculature of solid tumors. J Controlled Release 28:195–202, 1994.
Thorpe PE, Ross WC: The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol Rev 62:119–158, 1982.
Mulligan RC: The basic science of gene therapy. Science 260:926–932, 1993.
Nabel EG, Plantz G, Nabel GJ: Site-specific gene expressionin vivo by direct gene transfer into the arterial wall. Science 249:1285–1288, 1990.